AC Immune SA
(NASDAQ:ACIU)
$2.35
0.05 (2.17%)
At Close: 4:00 PM
$2.50
0.32 (14.68%)
Pre Market: 4:38 AM
ACIU Stock Price Graph
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- YTD
- All
ACIU Stock Price Today
AC Immune SA (ACIU) stock rallied over 2.17% intraday to trade at $2.35 a share on NASDAQ. The stock opened with a gain of 0.43% at $2.31 and touched an intraday high of $2.39, rising 2.17% against the last close of $2.30. The AC Immune SA in stock market went to a low of $2.25 during the session.
ACIU Stock Snapshot
$2.30
Prev. Close
176.34 Million
Market Cap
$2.25
Day Low
$2.31
Open
83.39 Million
Number of Shares
$2.39
Day High
N/A
P/E ratio
-0.93
EPS (TTM)
1.26
Cash Flow per Share
0.54
Free Float in %
1.83
Book Value
131609.00
Volume
ACIU Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| 2023-02-15 | $2.27 | $2.37 | $2.25 | $2.31 | 36566.00 |
| 2023-02-14 | $2.39 | $2.39 | $2.20 | $2.31 | 53400.00 |
| 2023-02-13 | $2.46 | $2.46 | $2.33 | $2.39 | 59200.00 |
| 2023-02-10 | $2.42 | $2.47 | $2.35 | $2.35 | 38800.00 |
| 2023-02-08 | $2.38 | $2.53 | $2.30 | $2.38 | 50753.00 |
| 2023-02-07 | $2.40 | $2.45 | $2.35 | $2.42 | 27300.00 |
| 2023-02-06 | $2.41 | $2.45 | $2.35 | $2.37 | 186300.00 |
| 2023-02-03 | $2.47 | $2.54 | $2.36 | $2.43 | 86235.00 |
| 2023-02-02 | $2.45 | $2.51 | $2.32 | $2.48 | 182100.00 |
| 2023-02-01 | $2.52 | $2.52 | $2.36 | $2.49 | 50600.00 |
Contact Details
Company Information
Employees126.00
Beta0.57
Sales or Revenue$3.94 Million
5Y Sales Change-27.90%
Fiscal Year EndsDec. 2022
SectorHealthcare
IndustryBiotechnology
About Company
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Frequently Asked Questions
What is the current AC Immune SA (ACIU) stock price?
AC Immune SA (NASDAQ: ACIU) stock price is $2.35 in the last trading session. During the trading session, ACIU stock reached the peak price of $2.39 while $2.25 was the lowest point it dropped to. The percentage change in ACIU stock occurred in the recent session was 2.17% while the dollar amount for the price change in ACIU stock was $0.05.
ACIU's industry and sector of operation?
The NASDAQ listed ACIU is part of Biotechnology industry that operates in the broader Healthcare sector. AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Who are the executives of ACIU?
Mr. Christopher Roberts
Interim Chief Financial Officer & Vice President of Fin.
Mr. Julian Snow
Vice President of U.S. Fin. & Corporation Devel.
Dr. Andrea Pfeifer Ph.D.
Co-Founder, Chief Executive Officer & Director
Dr. Andrea Pfeifer Ph.D.
Co-Founder, CEO & Director
How ACIU did perform over past 52-week?
ACIU's closing price is 0.23% higher than its 52-week low of $1.68 where as its distance from 52-week high of $3.9 is -0.47%.
How many employees does ACIU have?
Number of ACIU employees currently stands at 126.00. ACIU operates from Building B</br>Lausanne, 1015</br>CH.
Link for ACIU official website?
Official Website of ACIU is: https://www.acimmune.com
How do I contact ACIU?
ACIU could be contacted at phone #41 21 345 91 21 and can also be accessed through its website. ACIU operates from Building B</br>Lausanne, 1015</br>CH.
How many shares of ACIU are traded daily?
ACIU stock volume for the day was 131609.00 shares. The average number of ACIU shares traded daily for last 3 months was 79.78 Thousands.
What is the market cap of ACIU currently?
The market value of ACIU currently stands at $176.34 Million with its latest stock price at $2.35 and 83.39 Million of its shares outstanding.